GlobeNewswire

LeoVegas publishes prospectus and new financial information in connection with application of admission to trading on Nasdaq Stockholm

Dela

LeoVegas AB (publ) (" LeoVegas ") has to Nasdaq Stockholm AB applied for admission to trading of LeoVegas' shares on the regulated market Nasdaq Stockholm. The Board of Directors of LeoVegas have in connection with the listing on Nasdaq Stockholm prepared a prospectus that today has been approved and registered by the Swedish Financial Supervisory Authority. The prospectus contains, due to regulatory requirements, new financial information as of 31 October 2017 attributable to LeoVegas' capital structure that has not previously been published. LeoVegas expects a formal approval from Nasdaq Stockholm at the latest by 31 January 2018.

The prospectus
The prospectus has been prepared in connection with the application of change in listing from Nasdaq First North Premier to Nasdaq Stockholm. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and published on www.leovegasgroup.com. The prospectus will also within a few days be available on the Swedish Financial Supervisory Authority's web page, www.fi.se.

New financial information
The prospectus includes updated information as of 31 October 2017 attributable to LeoVegas' capital structure. This is due to regulatory requirements which implies that financial information attributable to the capital structure may not be older than 90 days upon the date of the prospectus. This information has previously not been published and the table presented below reproduces this information. The tables only include interest-bearing debts. In essence, the financial figures below reflect what was published in LeoVegas' interim-report for the period 1 January - 30 September 2017.

The tables of equity and liabilities as well as net indebtedness can be found on page 64 of the prospectus.

KEUR 31 Oct 2017 Proforma [1]
Current debt    
Guaranteed - -
Secured - -
Unguaranteed/Unsecured - -
Total Current debt - -
     
KEUR    
Non-Current debt    
Current debt - -
Guaranteed - -
Secured - 75 000
Total Non-Current debt - 75 000
     
Shareholder's equity    
Share capital 1 196   1 196 
Legal Reserve 36 588    36 588 
Other Reserves 19 610    19 610 
Total Shareholders' equity   57 394    57 394 

KEUR 31 Oct 17 Proforma [2]
(A) Cash 63 566  34 580
(B) Cash equivalent -
(C) Trading securities -5 399  -7 699
(D) Liquidity (A)+(B)+(C) 58 167  26 881
     
(E) Current Financial Receivable  - -
     
(F) Current Bank debt  - -
(G) Current portion of non current debt - -
(H) Other current financial debt - -
(I) Current Financial Debt (F)+(G)+(H) - -
     
(J) Net Current Financial Indebtedness (I)-(E)-(D) -58 167  -26 881 
     
(K) Non current Bank Loans - -75 000
(L) Bonds Issued  -
(M) Other non current loans  -
     
(N) Non current Financial Indebtedness (K)+(L)+(M) - -75 000
     
(O) Net Financial Indebtedness (J)+(N) -58 167  -101 881 

The prospectus also includes consolidated pro forma financial statements for LeoVegas regarding the acquisition of Royal Panda and Rocket X including a consolidated pro forma income statement for the period January 2017 - September 2017 and a consolidated pro forma balance sheet as of 30 September, 2017.

Trading on Nasdaq Stockholm
LeoVegas expects a formal approval from Nasdaq Stockholm at the latest AB on by 31 January 2018. Provided that an approval is obtained, the last day of trading on First North Premier is expected to be on 2 February 2018, and the first day for trading on Nasdaq Stockholm is planned to commence on 5 February 2018. LeoVegas' shares will be traded under the same ticker (LEO) and ISIN code (SE0008091904). LeoVegas shareholders do not need to take any action in connection with the change in listing.

Adviser
Baker McKenzie is acting as legal adviser to LeoVegas in connection with the change in listing to Nasdaq Stockholm.

For further information, please contact:

Gustaf Hagman, Group CEO co-founder: +46 70 880 55 22, gustaf.hagman@leovegas.com
Philip Doftvik, Head of Investor Relations: +46 73 512 07 20, philip.doftvik@leovegas.com
Visitors address: Luntmakargatan 18, Stockholm
Corporate identity number: 556830-4033

About the LeoVegas mobile gaming group
LeoVegas' passion is "Leading the way into the mobile future". LeoVegas is Sweden's premier GameTech company and is at the forefront of using state-of-the-art technology for mobile gaming. In 2017 the company passed the threshold for being classified as a unicorn, i.e., a start-up valued at more than USD 1 billion. A large part of this success can be credited to an extreme product and technology focus coupled with effective and data-driven marketing. Technology development is conducted in Sweden, while operations are based in Malta. LeoVegas offers casino, live casino and sport gaming, and operates two global and scalable brands - LeoVegas and Royal Panda. The company's shares are listed on Nasdaq First North Premier, and Avanza Bank AB is the company's Certified Adviser. For more about LeoVegas, visit  www.leovegasgroup.com .



[1] This information is presented as a result of the acquisitions of Royal Panda and Rocket X which occurred after 31 October 2017.  

[2] This information is presented due to of the acquisitions of Royal Panda and Rocket X which occurred after 31 October 2017.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LeoVegas AB via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum